Published
April 4, 2026
Updated
November 7, 2026
Where the $35 million Teva QVAR antitrust settlement stands: the claim window closed July 31, 2026, the court granted final approval on August 5, 2026, and no payment date has been announced.
Status
Final Approval Granted — Payments Pending
final approval granted August 5, 2026 · no payment date announced
Claim Deadline
July 31, 2026 (Closed)
final approval hearing held August 5, 2026 before Judge Nathaniel M. Gorton
Settlement Fund
$35 Million
plus Teva's reported agreement to withdraw certain QVAR-related patents from the FDA Orange Book
Proof Required
Yes
proof of purchase is required for consumer claims — claims could be filed first, but the administrator requests records (pharmacy/insurer records, EOBs, prescription history, receipts), and undocumented claims may be audited, reduced, or rejected · no Claim ID needed · third-party payors must submit transaction data
What's New: Final Approval Granted
November 7, 2026 update: Claims are closed; the deadline was July 31, 2026. Judge Nathaniel M. Gorton held the fairness hearing on August 5, 2026 and the same day entered the Order Granting Final Approval and Judgment (ECF 219), finding that no objections had been submitted, and the Order Awarding Attorney Fees (ECF 220), according to the court documents posted on the official settlement website. No payment date had been announced as of November 7, 2026.The fee order awarded Class Counsel $11,550,000 in attorneys' fees (33% of the $35 million fund) and $666,412.26 in litigation expenses, and approved service awards of $20,000 for each of the four class representatives. It makes the expenses and 57% of the fee payable on entry, with the remaining 43% of the fee payable on or about March 31, 2027, coinciding with Teva's final installment payment into the Settlement Fund.
Earlier update (May 25, 2026): The official QVAR antitrust settlement website at qvarantitrustsettlement.com went live and the claim form launched, following the court's April 2, 2026 preliminary approval of the settlement.
This page is a news update on case status and procedural milestones. For a full settlement guide — eligibility, the 41-state list, proof tiers, and how claims were filed — see our dedicated QVAR settlement page. For court documents, the full eligible-state list, and payment updates, the official administrator site at qvarantitrustsettlement.com is the controlling source.
What Is the QVAR Antitrust Settlement About?
QVAR is a prescription corticosteroid asthma inhaler manufactured by Teva. The end-payor litigation, filed in the U.S. District Court for the District of Massachusetts, alleges that Teva used a combination of product reformulations, strategic patent filings in the FDA's Orange Book, and litigation tactics to block or delay generic competitors from entering the market. When generic versions of a brand-name drug are kept off the market, consumers and insurers have no cheaper alternative and end up paying more than they should.In plain terms: generic inhalers that could have been available sooner were allegedly held back by Teva's actions. People with asthma who needed QVAR had to keep paying brand-name prices longer than necessary.
The FDA's "Orange Book" is a federal database listing patents tied to approved drugs. Brand-name manufacturers can list patents in the Orange Book to delay generic approval, because a generic applicant generally has to navigate around any Orange-Book-listed patent before the FDA will approve the generic. The lawsuit claims Teva listed patents in the Orange Book that should not have been there, which delayed generic companies from obtaining FDA approval for their versions of QVAR. The Federal Trade Commission has previously scrutinized some of these same Orange Book listings.
In addition to the $35 million cash fund, the settlement reportedly includes an agreement by Teva to withdraw certain QVAR-related patents from the Orange Book. That is significant beyond this settlement, because removing those patents could make it easier for generic QVAR to reach the market in the future.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Old Status vs. New Status: What Changed
For consumers who have been following the QVAR case, here is a before-and-after of where things stand after the court's August 5, 2026 final approval.| Item | Earlier Status (May 2026) | Current Status (November 2026) |
|---|---|---|
| Court approval stage | Preliminary approval granted April 2, 2026 | Final approval granted August 5, 2026 (ECF 219) |
| Settlement Website | QVAR Antitrust Settlement.com — live | QVAR Antitrust Settlement.com — live, with final approval and fee orders posted |
| Claim Form | Live on the official Settlement Website | Closed |
| Claim Deadline | July 31, 2026 | Passed (July 31, 2026) |
| Final Approval Hearing | Scheduled for August 5, 2026 | Held August 5, 2026 |
| Settlement Fund | $35 million (preliminarily approved) | $35 million (final approval granted) |
| Orange Book Patent Withdrawal | Part of preliminarily approved settlement terms | Part of the finally approved settlement terms |
Who Qualifies for the QVAR Settlement?
You may qualify if you purchased, paid for, or were reimbursed for QVAR asthma inhalers between January 1, 2015 and July 31, 2025, and you lived in one of the eligible states. The settlement covers both:• Individual consumers — people who bought QVAR out of pocket or through insurance copays
• Third-party payors — insurance companies, health plans, and other entities that reimbursed for QVAR prescriptions
The settlement reportedly covers 41 states plus Washington, DC. The full list of eligible states is published on the official Settlement Website's long-form notice. If your state is not on that list, you would not be part of this settlement class. Eligibility for end-payor antitrust settlements typically tracks state laws that allow indirect-purchaser recovery; not every state has such a law on its books.
How Much Could Each Person Get?
Individual payout amounts have not been announced. Here is what is known about the money:The total Settlement Fund is $35 million. On August 5, 2026, the court awarded $11,550,000 in attorneys' fees, $666,412.26 in litigation expenses and $20,000 service awards for each of the four class representatives, all paid from the fund, leaving roughly $22.7 million before administration costs and other deductions.
How much each person gets will depend on:
• The total number of valid claims filed
• How much each claimant spent on QVAR during the class period
• The court-approved plan of allocation (typically a pro rata distribution proportional to documented purchases)
Because the class potentially includes a large number of people across 41 states over a 10-year period, individual payments will vary widely. People who bought QVAR inhalers frequently and over many years will likely receive more than someone who filled a single prescription.
What Records Did Claims Require?
The claim window closed July 31, 2026. QVAR end-payor claims are documented purchase claims, and the administrator may request records to substantiate a submitted claim. Useful records include:• Pharmacy receipts or printouts showing the QVAR prescription and what you paid out of pocket
• Insurance Explanation of Benefits (EOB) statements showing QVAR prescription claims and the out-of-pocket portion
• Prescription history printouts from your pharmacy (most pharmacies will print or email a year-by-year history on request)
• Health Savings Account or Flexible Spending Account statements showing QVAR purchases reimbursed through pre-tax accounts
Pharmacies typically retain prescription records for several years, and many will provide a printable history covering multiple years on request.
What's Next in the QVAR Case
The court granted final approval of the $35 million settlement and ruled on Class Counsel's fee request on August 5, 2026. Distribution to approved claimants follows once the judgment becomes final and any appeals are resolved. No payment date had been announced as of November 7, 2026.Court documents and any payment schedule are posted on the official Settlement Administrator's site at qvarantitrustsettlement.com.
Watch Out for QVAR Settlement Scams
Settlement approvals and payment announcements attract scammers. A few common-sense rules:• Never pay a fee. Legitimate class action settlements never require an activation fee, processing fee, or "release fee" to file a claim or receive a settlement payment. Anyone asking for payment to "submit" or "expedite" your QVAR claim is running a scam.
• Never share your full Social Security Number, bank account password, or credit card number with anyone claiming to handle your QVAR settlement claim by phone, text, or email. The Settlement Administrator does not need that information to process your claim or mail your check.
• Use the official Settlement Website only: qvarantitrustsettlement.com. Type the URL directly. Be cautious of any email or text linking to a "QVAR settlement" page from a different domain.
• Be skeptical of "click here to claim your QVAR settlement" emails from unfamiliar senders.
• If you receive a check, verify it through your bank before depositing or cashing.
Other Related OCA Coverage
QVAR is one of several large pharmaceutical antitrust and pay-for-delay cases working through the courts. Class membership in one settlement does not affect eligibility for any other unrelated case.• Tracleer (Bosentan) Pay-for-Delay Settlement — $65M end-payer pay-for-delay settlement (third-party payors only)
• Teva, Granules & Heritage Metformin NDMA Settlement — $5.55M consumer settlement covering U.S. buyers of generic metformin (Jul 2015 – Jun 2020)
• OCA database of open class action settlements — complete list of active consumer cases
• Latest class action news and updates
Settlement Guide: QVAR Settlement Page
See the Full QVAR Settlement Page →
Frequently Asked Questions About the QVAR Settlement
Is the QVAR antitrust settlement claim form still open?
No. The claim deadline was July 31, 2026, and the claim window has closed. The court granted final approval of the $35 million Teva QVAR antitrust class action settlement on August 5, 2026. The official Settlement Website at qvarantitrustsettlement.com posts the case documents and any payment updates.
Who qualifies?
Consumers and third-party payors who purchased, paid for, or reimbursed for QVAR asthma inhalers between January 1, 2015 and July 31, 2025 in one of the 41 eligible states plus Washington, DC.
How much could each person get from the QVAR settlement?
Individual payout amounts have not been announced. The total Settlement Fund is $35 million. On August 5, 2026, the court awarded Class Counsel $11,550,000 in attorneys' fees (33% of the fund) and $666,412.26 in litigation expenses, and approved $20,000 service awards for each of the four class representatives, before administration costs and other deductions. Each claimant's share depends on the total number of valid claims, how much each claimant spent on QVAR during the class period, and the court-approved plan of allocation, so frequent QVAR buyers over many years will generally receive more than someone who filled a single prescription.
When did the court approve the QVAR antitrust settlement?
The U.S. District Court for the District of Massachusetts granted preliminary approval of the $35 million Teva QVAR antitrust class action settlement on April 2, 2026, which authorized the class notice program and opened the claim form. Judge Nathaniel M. Gorton then held the final approval (fairness) hearing on August 5, 2026 and entered the Order Granting Final Approval and Judgment the same day.
Do I need proof?
Yes. QVAR end-payor claims are documented purchase claims. Useful records include pharmacy receipts, insurance EOB statements, prescription history printouts, and HSA/FSA statements covering QVAR purchases during the class period.
When will QVAR settlement payments go out?
No payment date had been announced as of November 7, 2026. The court granted final approval on August 5, 2026. Distribution to approved claimants follows once the judgment becomes final and any appeals are resolved, and any payment schedule will be posted on the official Settlement Website.
What is the case name and court?
The case is Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al., No. 1:23-cv-11131-NMG, in the U.S. District Court for the District of Massachusetts before Judge Nathaniel M. Gorton.
Sources
• Official Settlement Website: QVARAntitrustSettlement.com• Reuters, "Teva agrees to pay $35 million to settle asthma inhaler antitrust lawsuit" (October 27, 2025)
• MLex coverage of preliminary approval (April 2, 2026)
• Order Granting Final Approval and Judgment (ECF 219) and Order Awarding Attorney Fees (ECF 220), both entered August 5, 2026: QVARAntitrustSettlement.com Court Documents
• FTC letter regarding Orange Book listings for QVAR RediHaler
• May 7, 2024 Memorandum and Order, U.S. District Court for the District of Massachusetts
• Defendant: Teva Pharmaceutical Industries Ltd. and related Teva entities
• Court: U.S. District Court for the District of Massachusetts
• FDA: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• FTC: Health Care and Pharmaceutical Competition
About This Page
This page reports on the Teva QVAR asthma inhaler antitrust class action settlement, from preliminary approval and the claim form launch through the court's August 5, 2026 final approval, for informational purposes. OpenClassActions.com is a consumer news site and is not the Settlement Administrator, Class Counsel, or a law firm. We do not process or decide claims. The official Settlement Website (qvarantitrustsettlement.com) and the case docket are the authoritative sources for the eligible-state list, allocation methods, and payment timing. The final approval and fee orders cited above are the court's own orders as posted on the official settlement website; the court docket in the District of Massachusetts is the primary record.
For more class actions keep scrolling below.
Status
Final Approval Granted — Payments Pending
Settlement Fund
$35,000,000
Case Title
Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al.
Case Number
1:23-cv-11131-NMG
Court
U.S. District Court, District of Massachusetts
Final Approval Hearing
Held August 5, 2026 · final approval granted August 5, 2026
Judge Nathaniel M. Gorton · Order Granting Final Approval and Judgment, ECF 219
Administrator
A.B. Data, Ltd.
Official Website
QVAR Antitrust Settlement.com
